2.7.5 参考文献

臨床薬理の概要

1) 【5.4-38】Faassen F, Vogel G, Spanings H, Vromans H. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003;263(1-2):113-22.
2) 【5.4-12】Christensen M, Tybring G, Mihara K et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 2002;71(3):141-52.
3) 【5.4-13】Granfors MT, Backman JT, Neuvonen M, Ahonen J and Neuvonen PJ. Fluvoxamine drastically increases concentrations and effects of tizanidine: A potentially hazardous interaction. Clin Pharmacol Ther 2004;75(4):331-41.
4) 【5.4-14】Backman JT, Karjalainen MJ, Neuvonen M, Laitila J and Neuvonen PJ. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol 2006;62(3):345-57.
5) 【5.4-15】Granfors MT, Backman JT, Neuvonen M and Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2–mediated presystemic metabolism. Clin Pharmacol Ther 2004;76(6):598-606.
6) 【5.4-16】Granfors MT, Backman JT, Laitila J and Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther 2005;78(4):400-11.
7) 【5.4-17】Venkatakrishnan K and Obach RS. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metabolism and Disposition 2005;33:845-52.

臨床的有効性

1) 【5.4-18】McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67-76
2) 【5.4-19】菊池美紀，木下裕久，石崎裕香，中根秀之，中根允文．統合失調症（精神分裂病）の疫学,経過. Pharma Medica 2002;20:13-7.
3) 【5.4-20】佐藤光源，丹羽真一，井上新平 編集，精神医学講座担当者会議 監修．統合失調症治療ガイドライン第 2 版．東京:医学書院;2008:7-16, 145-202
4) 【5.4-21】Argo TR, Crismon ML, Miller AL, Moore TA, Bendele SD, Suehs B. Texas Medication Algorithm Project Procedural manual: Schizophrenia Treatment Algorithms. Texas Department of State Health Services, 2008.
5) 【5.4-22】Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012 Jul;13(5):318-78.
6) 【5.4-23】Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ; WFSBP Task force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012

on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013 Feb;14(1):2-44.

7) 【5.4-24】The International Psychopharmacology Algorithm Project. IPAP Schizophrenia Algorithm. 2006
8) 【5.4-25】Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO et.al. American Psychiatric Association. Practice guidance for the treatment of patients with schizophrenia Second edition. APA, Washington DC. 2004.
9) 【5.4-26】Dixon L, Perkins D, Calmes C. Guideline Watch （September 2009）: Practice Guideline for The Treatment of Patients with Schizophrenia. American Psychiatric Association, 2009
10) 【5.4-27】Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry. 2003;64 Suppl 12:2-97.
11) 【5.4-28】稲垣中. 抗精神病薬の多剤大量投与の妥当性. Schizophrenia Frontier 2005;6:134-8.
12) 【5.4-29】吉尾隆. 抗精神病薬の多剤併用大量処方の実態 ; 精神科臨床薬学研究会（PCP 研究会）処方実態調査から. 精神神経学雑誌 2012; 114:690-5
13) 【5.4-30】新福尚隆, 浅井邦彦 編集, 世界の精神保健医療 現状理解と今後の展望 改訂第 2 版. 東京:へるす出版;2009:138-56
14) 【5.4-31】藤井千太, 新福尚隆. わが国における入院中の統合失調症患者に対する薬物療法の特徴, 海外諸国との比較から. 臨床精神薬理 2004;7:3-14.
15) 【5.4-32】Lee CK, Kwak YS, Yamamoto J, Rhee H, Kim YS, Han JH, Choi JO, Lee YH. Psychiatric epidemiology in Korea. Part II: Urban and rural differences. J Nerv Ment Dis. 1990 Apr;178(4):247-52.
16) 【5.4-33】Chien IC, Chou YJ, Lin CH, Bih SH, Chou P, Chang HJ. Prevalence and incidence of schizophrenia among national health insurance enrollees in Taiwan, 1996-2001. Psychiatry Clin Neurosci. 2004 Dec;58(6):611-8.
17) 【5.4-34】Shinfuku N, Tan CH. Pharmacotherapy for schizophrenic inpatients in East Asia--changes and challenges. Int Rev Psychiatry. 2008 Oct;20(5):460-8.
18) 【5.4-35】Park SC, Lee MS, Kang SG, Lee SH. Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review and assessment service-national patient sample. J Korean Med Sci. 2014 May;29(5):719-28.
19) 【5.4-36】Wang PS, Wu SL, Ching HY. The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia. Int Clin Psychopharmacol. 2014 Jul;29(4):235-8.
20) 【5.4-37】鄭文輝, 朱澤民. 台湾の医療保険制度. 医療と社会. 2008;18:143-88.